AMAG Pharmaceuticals Inc. closed a licensing agreement with Endoceutics Inc. for exclusive U.S. commercial rights to Intrarosa, a drug for the treatment of moderate-to-severe dyspareunia, a common symptom of vulvar and vaginal atrophy, due to menopause.

Intrarosa was approved in November 2016 and AMAG expects to launch Intrarosa in the U.S. in mid-2017.

Endoceutics and AMAG have also agreed to co-develop the product as a potential treatment for female sexual dysfunction in post-menopausal women.